Market Research Logo

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2015

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2015’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic’s Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuromyelitis Optica (Devic’s Syndrome) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuromyelitis Optica (Devic’s Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuromyelitis Optica (Devic’s Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Neuromyelitis Optica (Devic’s Syndrome) Overview
Therapeutics Development
Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Overview
Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Development by Companies
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Investigation by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Neuromyelitis Optica (Devic’s Syndrome) - Products under Development by Companies
Neuromyelitis Optica (Devic’s Syndrome) - Products under Investigation by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
Chugai Pharmaceutical Co., Ltd.
Genmab A/S
HanAll Biopharma Co., Ltd.
Karus Therapeutics Limited
MedImmune, LLC
Opexa Therapeutics, Inc.
Shire Plc
Takeda Pharmaceutical Company Limited
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dalfampridine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Neutrophil Elastase for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KA-1463 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPX-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SA-237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neuromyelitis Optica (Devic’s Syndrome) - Recent Pipeline Updates
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
Featured News & Press Releases
Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion
Jul 16, 2013: Alexion’s Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica
Jun 27, 2013: Alexion Pharma's Soliris Receives FDA Orphan Drug Designation For Treatment Of Neuromyelitis Optica
Oct 09, 2012: Alexion Pharma Announces Presentation Of Phase II Study Data Of Eculizumab In Patients With Relapsing Neuromyelitis Optica At ANA Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2015
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Genmab A/S, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune, LLC, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Shire Plc, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics - Recent Pipeline Updates, H2 2015
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2015
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report